Cargando…

IgA nephropathy: a perspective for 2021

Detalles Bibliográficos
Autores principales:	Floege, Jürgen, Barratt, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Introduction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551095/ https://www.ncbi.nlm.nih.gov/pubmed/34705062 http://dx.doi.org/10.1007/s00281-021-00890-9

Ejemplares similares

Why Target the Gut to Treat IgA Nephropathy?
por: Barratt, Jonathan, et al.
Publicado: (2020)

Current treatment of IgA nephropathy
por: Floege, Jürgen, et al.
Publicado: (2021)

New strategies and perspectives on managing IgA nephropathy
por: Selvaskandan, Haresh, et al.
Publicado: (2019)

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
por: Pawluczyk, Izabella Z. A., et al.
Publicado: (2021)

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
por: Floege, Jürgen, et al.
Publicado: (2022)

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
por: Lafayette, Richard A., et al.
Publicado: (2020)

New insights into the pathogenesis of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2017)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Challenges in IgA Nephropathy Management: An Era of Complement Inhibition
por: Tesař, Vladimir, et al.
Publicado: (2023)

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
por: Kim, Min Jeong, et al.
Publicado: (2016)

New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy
por: Scionti, Katrin, et al.
Publicado: (2021)

IgA Nephropathy: A Chinese Perspective
por: Zhang, Zhao, et al.
Publicado: (2021)

Targeting the Endothelin A Receptor in IgA Nephropathy
por: Kohan, Donald E., et al.
Publicado: (2023)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
por: Cheung, Chee Kay, et al.
Publicado: (2021)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
por: Selvaskandan, Haresh, et al.
Publicado: (2020)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
por: Lennartz, David Paul, et al.
Publicado: (2020)

Intestinal permeability in patients with IgA nephropathy and other glomerular diseases: an observational study
por: Seikrit, Claudia, et al.
Publicado: (2022)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

2021 National Association of Specialty Pharmacy: Research Presentation Abstracts
por: Arquette, Sheila, et al.
Publicado: (2021)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

Bibliometric Analysis of Research Relating to IgA Nephropathy from 2010 to 2021
por: Xi, Mengdan, et al.
Publicado: (2022)

An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective
por: Huang, Xin, et al.
Publicado: (2021)

Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives
por: Gan, Ting, et al.
Publicado: (2020)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy
por: Yeo, See Cheng, et al.
Publicado: (2023)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
por: Barratt, Jonathan, et al.
Publicado: (2019)

MicroRNAs in IgA nephropathy
por: Yao, Xingchen, et al.
Publicado: (2021)

Complement activation in IgA nephropathy
por: Medjeral-Thomas, Nicholas R., et al.
Publicado: (2021)

Erythrocytosis associated with IgA nephropathy
por: Cohen, Camille, et al.
Publicado: (2021)

Thrombotic Microangiopathy in IgA Nephropathy
por: Nasri, Hamid
Publicado: (2013)

Role of complement in IgA nephropathy
por: Daha, Mohamed R., et al.
Publicado: (2015)

Nutcracker phenomenon in IgA nephropathy
por: Imai, Naohiko, et al.
Publicado: (2014)

Idiopathic erythrocytosis in IgA nephropathy
por: Mahesh, E., et al.
Publicado: (2017)

Case Presentation – IgA Nephropathy
por: Williams, David L.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_pdqq2gupqg93ipmsj0r58svsmc